AbbVie Receives Designation for Upadacitinib as Rare Disease Treatment for Takayasu Arteritis AbbVie has secured rare disease designation for Upadacitinib targeting Takayasu arteritis, a condition with limited treatment options for patients in Japan.

AbbVie Receives Designation for Upadacitinib as Rare Disease Treatment for Takayasu Arteritis #Japan #Tokyo #AbbVie #Upadacitinib #Takayasu_Arteritis